GB Sciences, Inc. (OTCPK: GBLX)
Health Care · Pharmaceuticals · US
$0.00
-25.00% today · +50.0% 1Y
GB Sciences, Inc. (OTCPK: GBLX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $158.82K and employs 2 people.
Over the last twelve months the share price has gained 50.0%, trading between 0.00 and 0.50.
Tweenvest scores GB Sciences, Inc. across four factors: quality 18/100, value 45/100. Its strongest factor is value.
GBLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $158.82K
- Revenue (TTM)
- $97.23K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 10.72
- 52-week high
- $0.50
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 529.41M
- Employees
- 2
- Next earnings
- —
About GB Sciences, Inc.
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
- ISIN
- US3615441090
- Listed since
- May 12, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.